Anvisa suspends batch of drug for breast cancerAfter complaints about failures, The product was suspended.
The Letrozole medicine is with the lot 397733 suspended throughout the country. The National Health Surveillance Agency (Anvisa) banned the distribution, marketing and product use that lot.
The resolution was published in the Official Gazette, after complaints about faults in sealing the aluminum blister (pack the tablets with) no lOT, which is valid until June 2017. The box contains 30 tablets 2,5 milligrams.
The Letrozole is indicated for the treatment of advanced breast cancer in women who have gone through menopause, which they have been treated with inhibitors of estrogen hormone drugs.
Anvisa determined that the manufacturer's batch laboratory, the Eurofarma, collecting all the stock that is in pharmacies.
in a statement, the collected said Eurofarma entire batch, voluntarily, even before Anvisa recommendation, and that all customers were informed about the suspension. According to the laboratory, measures to correct the problem have been made and new batches have been produced and distributed in September.